Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Concord Medical hosts Twelfth Annual CCM Academic Conference in Beijing

Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that it hosted the Twelfth Annual CCM Academic Conference in Beijing on December 3 and 4, 2011.

5 Dec 2011

Lapatinib could extend survival in women with Her2-positive breast cancer

Treatment with lapatinib could extend survival in women with Her2-positive breast cancer that has spread to the brain, according to research published in the British Journal of Cancer.

30 Nov 2011

Combination of radiation treatment and LY2109761 can prevent glioblastoma

Glioblastoma is regarded as the most malignant form of brain tumor. In many cases, neurosurgeons are not able to remove such tumors completely because of the risk of destroying too much brain tissue in the process. Moreover, it is often impossible to identify all the fine extensions by which the tumor spreads into surrounding healthy tissue. To at least slow down the growth of tumor cells that have remained in the head, almost all glioblastoma patients are treated by radiotherapy after surgery.

24 Nov 2011

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.

21 Nov 2011

Researchers produce normal sperm from mouse cells

A Ben-Gurion University of the Negev researcher has achieved a significant breakthrough in male fertility, producing normal sperm from mouse cells.

16 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

First large scale trial of acupuncture for prevention of xerostomia

When given alongside radiation therapy for head and neck cancer, acupuncture has shown for the first time to reduce the debilitating side effect of xerostomia, according to new research from The University of Texas MD Anderson Cancer Center and Fudan University Shanghai Cancer Center.

11 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Research: Nucleolar disruption could destroy cancer cells

DAMAGING a cell's nucleolus could destroy cancer cells by increasing levels of the most important tumour prevention protein, p53, reveals research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, today.

7 Nov 2011

Blocking APE1 enzyme could provide new way to kill cancer cells

BLOCKING a key DNA damage repair enzyme, called APE1, could provide a new way to kill cancer cells containing faulty BRCA genes, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

7 Nov 2011

More than 36,000 people join Cancer Research UK's Voice for Radiotherapy campaign

More than 36,000 people have joined Cancer Research UK's Voice for Radiotherapy campaign to call on the government to improve radiotherapy services in England.

5 Nov 2011

Chemotherapy plus radiation improves overall survival for patients with stage II NPC

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

5 Nov 2011

EAU, ESTRO and ESMO to host European conference on urological cancers

The 3rd European Multidisciplinary Meeting on Urological Cancers will kick off this Friday, bringing together representatives of three adjacent fields involved in the management of prostate, bladder, kidney, testicular and penile cancer.

3 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

YM BioSciences announces results of nimotuzumab Phase II study on DIPG

YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.

31 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011

Varian to supply TrueBeam treatment systems to Lund University Hospital

Varian Medical Systems has been awarded a contract to supply four TrueBeam treatment systems to Lund University Hospital in Sweden, one of the country's largest radiotherapy departments. The order, confirmed in September, is aimed at cutting treatment waiting lists in the Skane region of Sweden and includes an option to acquire two further TrueBeam systems in 2014.

28 Oct 2011

NHS must plan to deal with predicted 45% leap in new cancer cases

The NHS must start planning now to deal with a predicted leap of 45 per cent in the number of new cancer cases in the UK over the next two decades, Cancer Research UK warns today (Friday).

28 Oct 2011